Floatz logo

107 assets in Malignant Glioma

Therapeutic assets addressing Malignant Glioma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Irinotecan
Malignant Glioma
Kailin Yang, MD, PhDP2BB (69)
Valaciclovir
Malignant Glioma
Trogenix ltdP2BB (65)
Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide
Malignant Glioma
Oblato, Inc.P2BB (64)
Nogitecan
Malignant Glioma
Jeffrey N. BruceP2B (63)
Nivolumab
Malignant Glioma
University of FloridaP2B (62)
Lomustine
Malignant Glioma
Actuate Therapeutics Inc.P2B (61)
Olaparib
Malignant Glioma
Fundación de investigación HMP2B (61)
AXUMIN
Malignant Glioma
Nicole HillP3B (60)
Dabrafenib
Malignant Glioma
National Cancer Institute (NCI)P4B (58)
db107-fc
Malignant Glioma
University of California, San FranciscoP2B (58)
db107-rrv
Malignant Glioma
University of California, San FranciscoP2B (58)
Everolimus
Malignant Glioma
Nationwide Children's HospitalP2B (58)
Ribociclib
Malignant Glioma
Nationwide Children's HospitalP2B (58)
Trametinib
Malignant Glioma
St. Jude Children's Research HospitalP4B (58)
Ipilimumab
Malignant Glioma
National Cancer Institute (NCI)P2B (57)
Palbociclib
Malignant Glioma
National Cancer Institute (NCI)P2B (57)
PI3K/MTOR INHIBITOR LY3023414
Malignant Glioma
National Cancer Institute (NCI)P2B (57)
Tazemetostat
Malignant Glioma
National Cancer Institute (NCI)P2B (57)
5-ala
Malignant Glioma
Alpheus Medical, Inc.P2CCC (55)
Vemurafenib
Malignant Glioma
National Cancer Institute (NCI)P2CCC (55)
Atezolizumab
Malignant Glioma
Mustafa Khasraw, MBChB, MD, FRCP, FRACPP1/2CCC (54)
Pembrolizumab
Malignant Glioma
Essen BiotechP1/2CCC (54)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Adriamycin
Malignant Glioma
Actuate Therapeutics Inc.P2CCC (53)
Carboplatin
Malignant Glioma
Actuate Therapeutics Inc.P2CCC (53)
Chlorophyllin Copper Complex Sodium
Malignant Glioma
Tata Memorial CentreP2CCC (53)
Cyclophosphamide
Malignant Glioma
Beijing BiotechP1/2CCC (53)
Ensartinib
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Fludarabine
Malignant Glioma
Beijing BiotechP1/2CCC (53)
g207
Malignant Glioma
Pediatric Brain Tumor ConsortiumP2CCC (53)
Ivosidenib
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Olutasidenib
Malignant Glioma
Rigel PharmaceuticalsP2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Selpercatinib
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Selumetinib
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Veliparib
Malignant Glioma
National Cancer Institute (NCI)P2CCC (53)
Elraglusib
Malignant Glioma
Actuate Therapeutics Inc.P2CCC (50)
Niraparib
Malignant Glioma
Armando Santoro, MDP1/2CCC (50)
Plixorafenib
Malignant Glioma
Fore BiotherapeuticsP2CCC (50)
Oxodotreotide
Malignant Glioma
Fundación de investigación HMP1/2CCC (48)
Pegargiminase
Malignant Glioma
Sabine Mueller, MD, PhDP1/2CCC (48)
pp65 rna lp
Malignant Glioma
University of FloridaP1/2CCC (48)
pp65/tumor mrna rna-lp
Malignant Glioma
University of FloridaP1/2CCC (48)
Tgx-007
Malignant Glioma
Trogenix ltdP1/2CCC (48)
TIL
Malignant Glioma
Essen BiotechP1/2CCC (48)
2-HYDROXYOLEIC ACID (SODIUM SALT)
Malignant Glioma
Laminar PharmaceuticalsP1/2CC (47)
Avutometinib
Malignant Glioma
Institute of Cancer Research, United KingdomP1/2CC (47)
Defactinib
Malignant Glioma
Institute of Cancer Research, United KingdomP1/2CC (47)
Showing 1 to 50 of 107 assets
PreviousPage 1 of 3Next